Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|HRAS mutant||transitional cell carcinoma||predicted - sensitive||Tipifarnib||Phase II||Actionable||In a Phase II trial (IST-01), Zarnestra (tipifarnib) treatment resulted in an objective response in 42% (5/12) of patients with urothelial carcinoma harboring HRAS mutations, with a median progression-free survival of 5.1 months (J Clin Oncol 38: 2020 (suppl; abstr 6504); NCT02535650).||detail...|
|PubMed Id||Reference Title||Details|
|Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.||Full reference...|